A randomized open-label study to investigate factors affecting adherence to monthly oral Bonviva [ibandronic acid] in women with post-menopausal osteoporosis
Phase of Trial: Phase IV
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms ATOM
- Sponsors Roche
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 20 Jun 2006 New trial record.